

REVIEW

Shrouq Khazaaleh, MD

Department of Internal Medicine,
Cleveland Clinic Fairview Hospital,
Cleveland, OH

Mohammad Alomari, MD

Department of Gastroenterology
and Hepatology, Cleveland Clinic Florida,
Weston, FL

Mamoon Ur Rashid, MD

Department of Gastroenterology
and Hepatology, Cleveland Clinic Florida,
Weston, FL

Daniel Castaneda, MD

Department of Gastroenterology
and Hepatology, Cone Health Annie Penn
Hospital, Reidsville, NC

Fernando J. Castro, MD

Department of Gastroenterology
and Hepatology, Cleveland Clinic Florida,
Weston, FL; Clinical Assistant Professor,
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University,
Cleveland, OH

Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting

ABSTRACT

Gastric intestinal metaplasia (GIM), a common histologic finding, is associated with increased risk of gastric cancer, and GIM associated with *Helicobacter pylori* infection is classified as an environmental metaplastic atrophic gastritis. Patients may be asymptomatic or present with various dyspeptic symptoms. Autoimmune metaplastic atrophic gastritis is a less common but important cause of chronic gastritis. The Correa cascade describes the evolution of precancerous mucosal changes that lead to development of GIM, with differentiation of 2 histologic types of GIM (complete and incomplete) and the consequences of each type. The risk of progression to malignancy is higher with incomplete GIM. It is also higher for those who immigrate from regions with a high incidence of *H pylori* infection to areas where the incidence is low. Guidelines regarding endoscopic management of GIM vary by geographic region.

KEY POINTS

Factors in the complex chain of events leading to malignant transformation include genetic predisposition, the anatomic extension of the metaplasia, and histologic differentiation.

Environmental risk factor control such as *H pylori* eradication, smoking cessation, and moderation in alcohol intake may halt the progression of atrophic gastritis to GIM.

Careful risk stratification is key: Patients at high risk should undergo endoscopic surveillance.

GASTRIC INTESTINAL METAPLASIA (GIM), a common histologic finding in clinical practice, is the differentiation of gastric epithelium into a form that resembles intestinal epithelium (Figure 1). It often represents a repair process in response to gastric injury such as from peptic ulcer or gastritis, and therefore most cases have no clinical significance. But if the gastric injury continues without treatment, GIM may be a warning sign of progression to gastric cancer, thus warranting further assessment and risk stratification. However, despite the risk of progression, malignancy develops in only a small minority of patients. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying high-risk patients who require endoscopic surveillance.

RISK OF CANCER PROGRESSION

Although uncommon, progression of GIM to gastric cancer is well documented. A total of 10 cohort studies, including 2 that were US-based, involving 25,912 patients with GIM, reported a pooled incidence rate of gastric cancer of more than 12 cases per 10,000 person-years.¹ Cancer progression is more likely in patients with GIM who develop dysplasia. In a study from the Netherlands, the annual incidence of gastric cancer was 0.25% with GIM, 0.6% with mild-to-moderate dysplasia, and 6% with severe dysplasia at baseline.²

Barrett esophagus has a similar histopathologic background and established cancer-

doi:10.3949/cjfm.91a.23015




Figure 1. Endoscopic appearance of gastric intestinal metaplasia (GIM). (A) White-light endoscopy reveals macroscopic GIM, with an irregular, even surface. The arrow indicates an elongated, groove-type pit pattern. (B) Enhanced narrow-band imaging of the same surface shows multiple pale, elevated patches.

TABLE 1
Autoimmune vs environmental metaplastic atrophic gastritis

	Autoimmune-mediated metaplastic atrophic gastritis	<i>Helicobacter pylori</i>-mediated metaplastic atrophic gastritis
Location	Primary involvement of the gastric body and fundus	All gastric epithelium including antrum
Acid production	Lost entirely	Decreased
Fasting gastrin level	Markedly elevated	Variable
Antibodies	Antibodies to intrinsic factor and parietal cells	Antibodies to <i>H pylori</i>
Vitamin B ₁₂ deficiency	Present, often severe	May be present, usually mild
Association	Other autoimmune disorders	Peptic ulcer disease, adenocarcinoma, "MALToma"

MALToma = mucosa-associated lymphoid tissue lymphoma or MALT lymphoma

Based on information in reference 15.

progression risk. The overall risk of progression to esophageal adenocarcinoma in Barrett esophagus is 0.22% per year.³ The presence of low-grade dysplasia increases the annual cancer risk to 0.5% per year, and high-grade dysplasia increases the risk to 5% to 8% per year.^{4,5} Although the risk of cancer progression with GIM and Barrett esophagus is similar in the United States, endoscopic surveillance only improved patient-important outcomes in Barrett esophagus, likely because of the lower prevalence of GIM compared with Barrett esophagus.^{1,6}

CHRONIC GASTRITIS AND GIM

Regardless of its cause, chronic gastric inflammation may lead to atrophic gastritis characterized by mucosal thinning and replacement of gastric glandular cells by intestinal epithelium (ie, GIM).

Environmental metaplastic atrophic gastritis

Helicobacter pylori infection remains the leading cause of chronic gastritis, with earlier studies suggesting that it is responsible for more than 90% of cases.⁷




Figure 2. The Correa cascade illustrates the progression from precancerous histologic changes in the gastric mucosa to the development of gastric intestinal metaplasia.

GIM as a result of *H pylori* infection is classified as an environmental metaplastic atrophic gastritis (EMAG). *H pylori* is more prevalent than previously thought, based on estimates that 50% of the world population has been infected in their lifetime,⁸ and the overall prevalence in the United States is 36%.⁹ If not eradicated, *H pylori* infection can progress to atrophic gastritis with damage to the gastric glands. Notably, the virulence of specific *H pylori* strains can play a critical role in infection outcomes. Strains that express the cytotoxin-associated gene *CagA* or the vacuolating cytotoxin *VacA* s1m1 genotype are associated with an increased risk of precancerous lesions and progression to adenocarcinoma.¹⁰

Chronic use of proton pump inhibitors (PPIs) has not been shown to prevent or modify histologic changes of GIM. In fact, chronic PPI use often results in decreased *H pylori* densities and proximal migration of the bacteria from the antrum to the body of the stomach, factors that complicate its diagnosis and timely eradication. Unmonitored long-term use of PPIs should be avoided.¹¹

TABLE 2
Risk factors for progression to malignancy in gastric intestinal metaplasia

	Relative risk	95% confidence interval
Incomplete gastric intestinal metaplasia ¹	3.33	1.96–5.64
Extensive gastric intestinal metaplasia ¹	2.07	0.97–4.42
Family history of a first-degree relative with gastric cancer ¹	4.5	1.3–15.5
Smoking ²⁶	1.57	1.24–1.98
Alcohol ²⁶	1.29	1.12–1.50

Other possible causes of EMAG include habits such as high salt intake, cigarette smoking, and alcohol use.¹²

Clinically, patients with EMAG may be asymptomatic or present with dyspeptic symptoms with variable severity. Autoantibodies to parietal cells and intrinsic factor are lacking, and levels of fasting gastrin tend to be low. In addition to evaluation for *H pylori* and its timely eradication, EMAG patients should be screened for coexisting conditions such as vitamin B₁₂ and iron deficiency and treated appropriately.

Autoimmune metaplastic atrophic gastritis

A less common but important cause of chronic gastritis is autoimmune metaplastic atrophic gastritis (AMAG). Affecting 0.15% of the adult population,¹³ AMAG primarily involves the gastric body and fundus while sparing the antrum. Most patients are asymptomatic, but some may present with manifestations of vitamin B₁₂ deficiency or iron-deficiency anemia. In contrast to laboratory findings for EMAG, supportive laboratory findings with AMAG include positive antibodies to intrinsic factor (more specific) and parietal cells (more sensitive), fasting hypergastrinemia, and decreased serum pepsinogen I/II ratio. Screening should be considered for concomitant autoimmune conditions such as type 1 diabetes mellitus and autoimmune thyroid disease.¹⁴ **Table 1** compares the features associated with EMAG and AMAG.¹⁵

TABLE 3
Variations in society recommendations for the management of gastric intestinal metaplasia

Geographic location	Society recommendations
East Asia	Endoscopic or radiographic screening of all men and women at age 50 or older ²⁹ In patients with gastric intestinal metaplasia and high-risk features, endoscopy recommended in 1 to 3 years
Europe	Patients with extensive gastric intestinal metaplasia should undergo endoscopic surveillance every 3 years Consider endoscopic surveillance in patients with gastric intestinal metaplasia limited to the corpus or antrum of the stomach but with a family history of gastric cancer, persistent <i>Helicobacter pylori</i> infection, incomplete gastric intestinal metaplasia, or autoimmune gastritis ³⁰
United States	AGA recommends against routine endoscopic surveillance after gastric intestinal metaplasia is detected in the general population, but if <i>H pylori</i> is detected, treatment is encouraged Patients with gastric intestinal metaplasia and risk factors associated with progression could be considered for endoscopic surveillance every 3 to 5 years if the patient favors surveillance (which has an unclear impact on mortality risk) vs endoscopic evaluation, which has a risk of complications ³¹ ASGE recommends endoscopic surveillance exclusively in patients with risk factors, but not in the general cohort of patients in whom gastric intestinal metaplasia is detected ³²

AGA = American Gastroenterological Association; ASGE = American Society for Gastrointestinal Endoscopy

■ CORREA CASCADE: DIFFERENTIATING COMPLETE AND INCOMPLETE GIM

The Correa cascade describes the progression from precancerous histologic changes in the gastric mucosa to the development of GIM and its consequences, including adenocarcinoma (Figure 2). The process begins with development of nonatrophic gastritis and progresses to multifocal atrophic gastritis followed by GIM.

GIM can present 2 histologic types:

- The *complete* and fully intestinalized pattern has markers for intestinal mucin and absence of gastric mucin.
- The *incomplete* gastric and intestinal mixed glands pattern has both gastric mucin and intestinal mucin markers.¹⁶

Complete GIM may progress to incomplete GIM if conditions leading to severe inflammation are present (eg, advanced atrophy or hypochlorhydria) before identifiable dysplastic changes.¹⁷ Subsequently, the tissue progresses to low-grade dysplasia, followed by high-grade dysplasia, and finally invasive adenocarcinoma.¹⁸

Differentiation of the 2 types of GIM is important. Incomplete GIM has been associated with an increased risk of cancer progression, and some experts consider it a mild degree of dysplasia.^{19,20}

■ RISK FACTORS FOR PROGRESSION TO MALIGNANCY

The risk of developing gastric cancer may be higher in patients with histologic evidence of incomplete and extensive GIM (ie, involvement of the antrum and corpus) than in those with complete and limited GIM.^{1,21,22} Some studies suggest that the topographic distribution of intestinal metaplasia may affect the risk of cancer progression. In Cassaro et al's²³ cohort study of 135 Colombian patients, a GIM distribution involving the lesser curvature of the stomach from the cardia to the pylorus was associated with higher cancer risk (odds ratio 5.7, 95% confidence interval 1.3–26) compared with “antrum-predominant” or “focal” patterns.²³

The incidence of gastric cancer exhibits significant geographic variation worldwide due to potential environmental exposure factors and genetic predisposition. The reported rates are highest in Eastern Asia, Eastern Europe, and South America, and lowest in North America.²⁴ People who immigrate from a region of high incidence to a region of low incidence have an increased risk of gastric cancer.²⁵ Table 2 summarizes risk factors for malignancy.^{1,26}




Figure 3. An algorithmic approach to the management of gastric intestinal metaplasia (GIM).

■ ENDOSCOPIC MANAGEMENT

The role for endoscopy in GIM is limited to detection and surveillance, as no other methods are currently available for this. Specific recommendations for endoscopy are discussed in the various guidelines below.

■ NONENDOSCOPIC MANAGEMENT

GIM management should emphasize risk-factor modification, including smoking cessation and moderation in alcohol intake. In patients with *H pylori*-induced gastritis, early *H pylori* detection and eradication are crucial to halt progression to gastric cancer. In contrast, the effects of *H pylori* eradication once GIM occurs are undetermined. GIM changes may

be irreversible, and the impact of *H pylori* eradication on cancer progression once GIM is established may be minimal.²⁷

Observational studies have reported partial GIM reversal and decreased progression to stomach cancer with use of aspirin and nonsteroidal anti-inflammatory drugs such as celecoxib.²⁸ More evidence is needed to support their use.

■ GLOBAL DIFFERENCES IN GUIDELINE RECOMMENDATIONS

The optimal follow-up of patients with isolated glands of GIM remains controversial, with significant differences in guidelines in the Eastern and Western regions of the world (Table 3).^{29–32}

Recommendations for Eastern regions

In countries such as Japan, where the incidence of gastric cancer is high, national screening programs recommend mass endoscopic or radiographic screening of all men and women at age 50 or older.²⁹ For patients found to have GIM without malignancy on initial screening, surveillance endoscopy in 1 to 3 years is recommended if they have GIM with high-risk features such as incomplete GIM, extensive GIM, family history of gastric cancer, smoking, or excessive alcohol use.

Recommendations for Western regions

The British Society of Gastroenterology guidelines³³ identify patients with GIM as having increased risk for gastric malignancy and recommend endoscopic surveillance every 3 years if there is extensive GIM (ie, affecting the antrum and corpus), antral GIM with risk factors such as *H pylori*, or a family history of gastric cancer.³³

A 2019 consensus guideline by 4 European organizations agreed with the British Society of Gastroenterology.³⁰ The guideline recommends that patients with GIM who are considered at high risk, including those with histologically proven GIM of the corpus and antrum, undergo endoscopic surveillance every 3 years. The guideline advises consideration of surveillance if GIM is present only in the corpus or antrum but the patient has a family history of gastric cancer, persistent *H pylori*, incomplete GIM, or autoimmune gastritis.

US recommendations

Two US societies have published guidelines addressing the management of GIM.

The American Gastroenterological Association guidelines³¹ recommend against routine endoscopic surveillance after GIM is detected in the general population, but if *H pylori* is detected, treatment is encouraged. Patients with GIM and risk factors associated with progression can be considered for endoscopic surveillance every 3 to 5 years if the patient favors surveillance, which has an unclear impact on mortality

risk, vs endoscopic evaluation, which has potential complications.³¹

The guidelines subcategorized risk factors associated with progression of gastric cancer as follows:

- Highest risk: incomplete GIM, extensive GIM, or family history of gastric cancer
- Overall increased risk: certain racial or ethnic minorities immigrating from high-incidence regions.³¹

The American Society for Gastrointestinal Endoscopy recommendations³² are similar to those of European groups. They advise endoscopic surveillance exclusively for patients with risk factors, but not for the general cohort of patients in whom GIM is detected.

AN ALGORITHMIC APPROACH TO DIAGNOSIS AND MANAGEMENT

Figure 3 suggests an approach to managing patients who have GIM. The updated Sydney protocol includes the collection of 5 nontargeted biopsy specimens: 2 from the antrum (at the lesser and greater curvature), 2 from the corpus (at the lesser and greater curvature), and 1 from the incisura.³⁴ It is recommended that these biopsy specimens be placed in separate jars.

Careful inspection should be carried out with high-definition white-light endoscopy rather than standard-definition endoscopy. Adequate air insufflation, use of mucolytic and defoaming agents (for improved visibility), appropriate withdrawal times, and photodocumentation are key for a quality endoscopic examination.³⁵ Additionally, use of narrow-band imaging should be encouraged because it has been shown to improve the detection of GIM.³⁶ It also allows for more targeted biopsies for GIM.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES

1. Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia: natural history and clinical outcomes. *Gastroenterology* 2020; 158(3):705–731.e5. doi:10.1053/j.gastro.2019.12.001
2. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; 134(4):945–952. doi:10.1053/j.gastro.2008.01.071
3. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study [published correction appears in *J Natl Cancer Inst* 2013; 105(8):581]. *J Natl Cancer Inst* 2011; 103(13):1049–1057. doi:10.1093/jnci/djr203
4. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. *Gastrointest Endosc* 2008; 67(3):394–398. doi:10.1016/j.gie.2007.07.019
5. Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. *Gastrointest Endosc* 2014; 79(6):897–983.e3. doi:10.1016/j.gie.2014.01.009
6. El-Serag HB, Naik AD, Duan Z, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. *Gut* 2016; 65(8):1252–1260. doi:10.1136/gutjnl-2014-308865
7. Sipponen P, Maarros HI. Chronic gastritis. *Scand J Gastroenterol* 2015; 50(6):657–667. doi:10.3109/00365521.2015.1019918

8. **Brown LM.** *Helicobacter pylori*: epidemiology and routes of transmission. *Epidemiol Rev* 2000; 22(2):283–297. doi:10.1093/oxfordjournals.epirev.a018040
9. **Smith JG, Li W, Rosson RS.** Prevalence, clinical and endoscopic predictors of *Helicobacter pylori* infection in an urban population. *Conn Med* 2009; 73(3):133–137. pmid:19353987
10. **Murata-Kamiya N.** Pathophysiological functions of the CagA oncoprotein during infection by *Helicobacter pylori*. *Microbes Infect* 2011; 13(10):799–807. doi:10.1016/j.micinf.2011.03.011
11. **Nasser SC, Slim M, Nassif JG, Nasser SM.** Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. *World J Gastroenterol* 2015; 21(15):4599–4606. doi:10.3748/wjg.v21.i15.4599
12. **Correa P, Piazuelo MB, Wilson KT.** Pathology of gastric intestinal metaplasia: clinical implications. *Am J Gastroenterol* 2010; 105(3):493–498. doi:10.1038/ajg.2009.728
13. **Hayter SM, Cook MC.** Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. *Autoimmun Rev* 2012; 11(10):754–765. doi:10.1016/j.autrev.2012.02.001
14. **Park JY, Lam-Himlin D, Vemulapalli R.** Review of autoimmune metaplastic atrophic gastritis. *Gastrointest Endosc* 2013; 77(2):284–292. doi:10.1016/j.gie.2012.09.033
15. **Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR.** Autoimmune atrophic gastritis: current perspectives. *Clin Exp Gastroenterol* 2017; 10:19–27. doi:10.2147/CEG.S109123
16. **Reis CA, David L, Correa P, et al.** Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. *Cancer Res* 1999; 59(5):1003–1007. pmid:10070955
17. **Sugano K, Moss SF, Kuipers EJ.** Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer? *Gastroenterology* 2023; S0016-5085(23)04911-9. doi:10.1053/j.gastro.2023.08.028
18. **Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M.** A model for gastric cancer epidemiology. *Lancet* 1975; 2(7924):58–60. doi:10.1016/s0140-6736(75)90498-5
19. **Tava F, Luinetti O, Ghigna MR, et al.** Type or extension of intestinal metaplasia and immature/atypical “indefinite-for-dysplasia” lesions as predictors of gastric neoplasia. *Hum Pathol* 2006; 37(11):1489–1497. doi:10.1016/j.humpath.2006.05.012
20. **Tosi P, Filipe MI, Luzi P, et al.** Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. *J Pathol* 1993; 169(1):73–78. doi:10.1002/path.1711690112
21. **Silva S, Filipe MI, Pinho A.** Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow-up study. *Gut* 1990; 31(10):1097–1104. doi:10.1136/gut.31.10.1097
22. **González CA, Sanz-Anquela JM, Companioni O, et al.** Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. *J Gastroenterol Hepatol* 2016; 31(5):953–958. doi:10.1111/jgh.13249
23. **Cassaró M, Rügge M, Gutierrez O, Leandro G, Graham DY, Genta RM.** Topographic patterns of intestinal metaplasia and gastric cancer. *Am J Gastroenterol* 2000; 95(6):1431–1438. doi:10.1111/j.1572-0241.2000.02074.x
24. **Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.** Global cancer statistics [published correction appears in *CA Cancer J Clin* 2011; 61(2):134]. *CA Cancer J Clin* 2011; 61(2):69–90. doi:10.3322/caac.20107
25. **Pabla BS, Shah SC, Corral JE, Morgan DR.** Increased incidence and mortality of gastric cancer in immigrant populations from high to low regions of incidence: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2020; 18(2):347–359.e5. doi:10.1016/j.cgh.2019.05.032
26. **Altayar O, Davitkov P, Shah SC, et al.** AGA technical review on gastric intestinal metaplasia-epidemiology and risk factors. *Gastroenterology* 2020; 158(3):732–744.e16. doi:10.1053/j.gastro.2019.12.002
27. **Chen HN, Wang Z, Li X, Zhou ZG.** *Helicobacter pylori* eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. *Gastric Cancer* 2016; 19(1):166–175. doi:10.1007/s10120-015-0462-7
28. **Tian W, Zhao Y, Liu S, Li X.** Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. *Eur J Cancer Prev* 2010; 19(4):288–298. doi:10.1097/CEJ.0b013e328339648c
29. **Hamashima C.** Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan. *Jpn J Clin Oncol* 2018; 48(3):278–286. doi:10.1093/jjco/hyx190
30. **Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al.** Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. *Endoscopy* 2019; 51(4):365–388. doi:10.1055/a-0859-1883
31. **Gupta S, Li D, El Serag HB, et al.** AGA clinical practice guidelines on management of gastric intestinal metaplasia. *Gastroenterology* 2020; 158(3):693–702. doi:10.1053/j.gastro.2019.12.003
32. **ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al.** The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc* 2015; 82(1):1–8. doi:10.1016/j.gie.2015.03.1967
33. **Banks M, Graham D, Jansen M, et al.** British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. *Gut* 2019; 68(9):1545–1575. doi:10.1136/gutjnl-2018-318126
34. **Shah SC, Gawron AJ, Li D.** Surveillance of gastric intestinal metaplasia. *Am J Gastroenterol* 2020; 115(5):641–644. doi:10.14309/ajg.0000000000000540
35. **Veitch AM, Uedo N, Yao K, East JE.** Optimizing early upper gastrointestinal cancer detection at endoscopy. *Nat Rev Gastroenterol Hepatol* 2015; 12(11):660–667. doi:10.1038/nrgastro.2015.128
36. **Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al.** Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. *Gastrointest Endosc* 2017; 86(5):857–865. doi:10.1016/j.gie.2017.03.1528

Address: Mohammad Alomari, MD, Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331; dr_mohd1987@hotmail.com